Cardiol Therapeutics (CRDL)
(Delayed Data from NSDQ)
$2.09 USD
+0.09 (4.50%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $2.10 +0.01 (0.48%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CRDL 2.09 +0.09(4.50%)
Will CRDL be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CRDL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRDL
5 Small Drug Stocks to Buy From a Recovering Industry
Here's Why You May Invest in Cardiol Therapeutics (CRDL) Stock
CRDL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is it a Good Time to Invest in Aurinia Pharmaceuticals (AUPH)?
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Zacks Industry Outlook Highlights Corcept Therapeutics, Aurinia Pharmaceuticals, Alpine Immune Sciences, KalVista Pharmaceuticals and Cardiol Therapeutics
Other News for CRDL
Cardiol Therapeutics Gains Key Legal Consent
Cordel Group inks new customer contract with Genesee & Wyoming
Cardiol Therapeutics Shareholders Approve Resolutions
Cardiol Therapeutics initiated with bullish view at Roth MKM, here's why
Buy Rating on Cardiol Therapeutics: Promising CardioRx Pipeline and Positive Clinical Trials